Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANORAY-312: NBTXR3 + RT +/- Cetuximab in Elderly LA-HNSCC
NCT04892173Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Dec 2021
- Primary completion
- Jun 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of NBTXR3 in head and neck squamous cell carcinoma (HNSCC), sponsored by Johnson & Johnson. Started Dec 2021; status: recruiting.
02
Drugs
NBTXR3
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04892173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892173.